Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Starpharma Holdings Ltd's Dendrimer-Oxaliplatin Shows Better Anti-cancer Efficacy And Less Toxicity


Tuesday, 10 Sep 2013 08:05pm EDT 

Starpharma Holdings Ltd announced it had achieved improved tumour-inhibiting efficacy and reduced overall toxicity using a dendrimer enhanced version of the blockbuster cancer drug, oxaliplatin (ELOXATIN). These positive results were demonstrated in a pre-clinical study, which examined dendrimer-enhanced nanoparticle versions of oxaliplatin compared with ELOXATIN (oxaliplatin) in a colon cancer model (xenograft). Oxaliplatin is primarily used to treat colon and colorectal cancer. Bone marrow toxicities (including the serious white blood cell disorder, neutropenia1) are reported in a high proportion of patients receiving Oxaliplatin – with rates in excess of 70%. The observation that Starpharma’s Dendrimer-Enhanced Oxaliplatin nanoparticles substantially reduced neutropenia, a life threatening and dose-limiting toxicity is an important finding, both for this drug candidate (Dendrimer-Enhanced Oxaliplatin) and potentially also for Starpharma’s platform more broadly. These positive results achieved with Starpharma’s Dendrimer-Enhanced Oxaliplatin nanoparticles are the subject of a new patent filing and given the obvious commercial potential, Starpharma now intends to advance Dendrimer-Enhanced Oxaliplatin formulations into development. Additional studies are ongoing to further explore the positive impact on bone marrow toxicity and the potential for the Dendrimer-Enhanced nanoparticles to reduce certain other clinically important toxicities. 

Company Quote

0.52
0.0050 +0.97%
24 Dec 2014